Unlocking Lung Health: New Insights into CTEPH, CTED, and Innovative Therapies
"Discover the latest advancements in understanding chronic pulmonary conditions and potential treatments, including the promising role of amniotic epithelium cell secretome."
Pulmonary hypertension and chronic thromboembolic diseases pose significant challenges to the medical community. Recent studies highlight the importance of metabolomic profiling in identifying key metabolites and pathways involved in pulmonary arterial hypertension. These advancements pave the way for better diagnostic and therapeutic strategies.
Two related conditions, chronic thromboembolic pulmonary hypertension (CTEPH) and chronic thromboembolic vascular occlusions without pulmonary hypertension (CTED), have garnered increased attention. Researchers are diligently working to understand the metabolic differences between these conditions and how they impact overall health.
Adding another layer of innovation, scientists are exploring the potential therapeutic benefits of human amniotic epithelium cell secretome in ex-vivo lung perfusion. This novel approach could revolutionize how we treat and rehabilitate damaged lungs, offering new hope for patients awaiting transplants.
The Power of Health Statistics
Statistical tools are essential for making sense of health data: measures of spread such as population variance describe how much observations differ around a mean, helping researchers gauge the variability in any dataset. National statistics agencies compile official demographic figures, while public data platforms allow users to explore and compare population trends across cities and regions. Applying such data-driven analysis is how researchers track the burden of chronic diseases and assess whether outcomes are improving or worsening.
Standard Care: Imaging, Teams, and Tailored Treatment
CTEPH is classified as WHO Group 4 pulmonary hypertension, and current treatment principles call for combined or sequential approaches tailored to anatomy, operability, haemodynamics, and centre expertise. Multidisciplinary teamwork is a growing focus, with events such as CHEST 2026 planning interactive sessions that simulate a multidisciplinary team conference for diagnosing and managing CTEPH. Imaging is central to the diagnostic pathway, yet a critical review finds the strength of evidence supporting each imaging technique varies between studies and that many investigations carry methodological limitations. A retrospective analysis of 133 consecutive pulmonary hypertension patients also examined the sensitivity and specificity of V/Q scintigraphy and CTPA for CTEPH in Southeast Asian patients, illustrating how diagnostic performance continues to be tested in specific populations.
From Clots to Surgery: The Journey of Discovery
Educational sessions with specialists such as Dr. Timothy Fernandes of UC San Diego Health have helped clarify the relationships between acute deep vein thrombosis, pulmonary embolism, and the later conditions post-thrombotic syndrome, CTEPH, and CTED. Patient accounts illustrate the same underlying story: people who experience clotting problems later develop pulmonary hypertension caused by persistently high pressure in the lungs, and some ultimately undergo a surgical procedure offered to eligible CTEPH candidates. One patient described living with a blood clotting disorder and CTEPH symptoms before treatment, while another, Mr. Prakash Thakor of Vadodara, shared how successful CTEPH surgery at Apollo Hospitals changed his journey. Together these experiences highlight how recognition of CTEPH as a distinct complication of prior blood clots has grown over time.
Metabolic Insights into CTEPH and CTED
A comprehensive study was conducted to profile circulating metabolites in patients with CTEPH and CTED. Blood samples were collected from various locations, including the superior vena cava, pulmonary artery, and radial artery. These samples were then compared against those from healthy controls to identify significant metabolic differences.
- Increased acylcarnitines, long chain fatty acids, and polyamines.
- Reduced lysolipids, plasmalogens, and aminosugars.
- Changes in glutathione metabolites and steroids.
- Predominant clearance of energy metabolism related metabolites.
New Clues: Anticoagulation, Anatomy, and Imaging
Newer research links the risk of developing CTEPH after an acute pulmonary embolism to the quality of initial anticoagulant treatment, with one study following patients who had confirmed CTEPH (n = 44). Another recent finding is that May-Thurner anatomy, a compression of the iliac vein in the pelvis that predisposes to deep vein thrombosis, is common in patients with CTEPH, since the clots that cause the condition often originate in veins of the lower body. Clinically, CTEPH commonly presents with fatigue, chest pain, and shortness of breath, especially during exercise. On late-stage chest radiography, patients often show signs of pulmonary hypertension, cardiac chamber enlargement, and segmental oligemia with pleuroparenchymal scarring.
When Standard Care Falls Short
CTEPH represents a failure of the body to fully resolve pulmonary thromboemboli: incomplete resolution produces chronic, fibrotic, flow-limiting changes in the pulmonary vascular bed, a form of pre-capillary pulmonary hypertension. Risk factors such as recurrent pulmonary embolism and hypercoagulable states make this outcome more likely, underscoring gaps in standard prevention. Patient accounts make the stakes concrete, as with Janel, who was diagnosed with CTEPH only after her fourth pulmonary embolism, a condition described as causing debilitating breathing problems, heart failure, and even death. Such cases show that when acute clot management falls short, the consequences can be severe.
CTEPH in Comparison
Comparative analyses help clarify how CTEPH differs from other forms of pulmonary hypertension: patients with CTEPH generally have a lower mean pulmonary artery pressure than PAH patients and are typically older. On the treatment side, randomized data show that riociguat improves exercise capacity and WHO functional class compared with placebo in adults with persistent or recurrent CTEPH after surgical treatment, or inoperable CTEPH. These contrasts matter because they inform which patients are candidates for medical therapy versus surgery.
Future Therapeutic Directions
The potential therapeutic applications of human amniotic epithelium cell secretome are also under investigation. Studies suggest that this secretome may offer benefits during ex-vivo perfusion of donor lungs, potentially improving lung condition and viability for transplantation. This innovative approach represents a promising avenue for enhancing lung health and expanding the pool of available organs for those in need.
Expert Consensus: A Treatable Complication
Expert opinion from the Polish Cardiac Society working group emphasizes that CTEPH is a complication of acute pulmonary embolism for which effective and sometimes curative treatments exist, and that pulmonary endarterectomy (PEA) surgery remains the cornerstone of therapy in European and North American practice. A parallel expert-opinion review makes the same point, urging recognition of CTEPH as a complication of acute PE because effective, sometimes curative treatment is available. In the CHEST-1 study, operability assessment across 956 CTEPH patients showed that where no local expert CTEPH centre existed, central adjudication demonstrated the utility of remote expert opinion, a practical lesson for centres without specialized teams.
Biomarkers, Think Tanks, and the Curable Frontier
CTEPH is sometimes described as a potentially surgically curable form of pulmonary hypertension, which keeps the search for earlier detection and better outcomes urgent. Looking ahead, a study conducted in China identified two proteins associated with platelet aggregation and activation that may serve as biomarkers of CTEPH severity and progression, and that could become targets for future treatment. Collaborative efforts are also underway at a global scale, such as a Bayer-sponsored CTEPH Futures Think Tank that brought the CTEPH community together to debate how to do more for patients today and tomorrow.
The Post-PE Challenge and Research Landscape
Even with decades of refinement in acute management, the post-pulmonary-embolism landscape continues to challenge clinicians, characterized by persistent symptoms, functional limitation, and the ongoing risk of developing chronic thromboembolic pulmonary hypertension. This gap between acute care and long-term recovery sits within a broader research context: prior bibliometric studies of CTEPH have mainly described broad publication patterns and collaboration, whereas a newer analysis distinguishes itself by targeting the 100 most frequently cited articles. Such mapping of the literature helps reveal where knowledge is concentrated and where gaps in chronic care remain.
Real-World Lives Behind the Guidelines
Real-world data show that although treatment patterns for CTEPH generally follow recommended guidelines, several differences are observed in everyday practice, and many patients still experience exertional dyspnea, with the disease impacting their mobility. Such findings translate directly into how care is delivered: a real-world study called CAPTURE was designed to investigate how physicians manage switching patients to riociguat, reflecting that switching from one drug to another while discontinuing the first can be a viable and appropriate option in clinical practice. The gap between guideline-based care and what patients actually experience underscores the human cost of CTEPH.